E
CCCC icon

Ergoteles’s C4 Therapeutics CCCC Stock Holding History

Ergoteles’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-79,770
Closed -$250K – 1088
2023
Q1 		$250K Buy
+79,770
New +$470K 0.01% 947
2022
Q3 		– Sell
-43,500
Closed -$328K – 1584
2022
Q2 		$328K Buy
+43,500
New +$383K 0.01% 1059

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Ergoteles's CCCC Position: Q2 2023 in Review

Ergoteles sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 79,770 shares — an estimated $250K sold.

Ergoteles first reported a position in CCCC in Q2 2022 and held it in 2 quarters. The position peaked at $328K in Q2 2022. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Ergoteles reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 79,770 C4 Therapeutics shares in Q2 2023, an estimated $250K.
  • Ergoteles first reported a position in C4 Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ergoteles's C4 Therapeutics position peaked at $328K in Q2 2022.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.